Patent ID: 8728482

Claim:
A method of treating or diagnosing a disease selected from the group consisting of an inflammatory disease, an immune disease, and a malignant disease, wherein the disease is associated with TL1A, and wherein the method comprises administering to a subject in need thereof a composition comprising: (A) an isolated antigen-binding polypeptide that binds specifically to TL1A comprising: (1) a humanized heavy chain variable region comprising (a) CDR-H1 comprises the amino acid sequence LYGMN (SEQ ID NO:11) or NYGMN (SEQ ID NO:12); (b) CDR-H2 comprises the amino acid sequence (WINTYTGEPTYADDFKG) (SEQ ID NO:13); and (c) CDR-H3 comprises the amino acid sequence DTAMDYAMAY (SEQ ID NO:14) or DYGKYGDYYAMDY (SEQ ID NO:15); and (2) a humanized light chain variable region comprising (d) CDR-L1 comprises the amino acid sequence KSSQNIVHSDGNTYLE (SEQ ID NO:16) or RSSQSIVHSNGNTYLD (SEQ ID NO:17); (e) CDR-L2 comprises the amino acid sequence KVSNRFS (SEQ ID NO:18); and (f) CDR-L3 comprises the amino acid sequence FQGSHVPLT (SEQ ID NO:19); and (B) at least one pharmaceutically acceptable carrier.